8-K: Cellectar Biosciences Advances Cancer Drug Trials, Secures Funding

Cellectar Biosciences reported Q2 2026 results, highlighting progress in its iopofosine I 131 and CLR 125 trials, initiation of Phase 3 site activation, and a significant capital raise.

Summary

• Cellectar Biosciences announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update.
• Key developments include the initiation of site activation for the confirmatory Phase 3 study of iopofosine I 131 for Waldenstrm Macroglobulinemia (WM), with a planned New Drug Application (NDA) submission in mid-2027 under the FDA's Accelerated Approval Program.
• Data from the CLOVER WaM trial of iopofosine I 131 in relapsed/refractory WM was presented at ASCO 2026, showing a 79.2% Major Response Rate (MRR) in evaluable patients.
• The company also initiated enrollment and dosed the first patients in a Phase 1b clinical trial of CLR 125 in Triple Negative Breast Cancer (TNBC).
• Phase 1 data for iopofosine I 131 in relapsed/refractory multiple myeloma (r/r MM) was published in the journal Cancers, demonstrating disease control in 84.6% of evaluable patients.
• Cellectar secured approximately $35 million upfront and up to $105 million in milestone-based securities in a registered direct offering and concurrent private placement in May 2026, primarily to fund the Phase 3 iopofosine I 131 study.
• As of June 30, 2026, the company had $34.0 million in cash and cash equivalents, sufficient to fund operations into Q2 2027.
• Research and Development expenses increased to $4.6 million for Q2 2026, driven by new study initiations, while General and Administrative expenses decreased to $2.6 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by significant progress in clinical trials and a strengthened financial position, though the net loss and ongoing R&D expenses warrant attention.

Positives

• Initiated site activation for the confirmatory Phase 3 study of iopofosine I 131, a critical step towards an NDA submission.
• Presented compelling Phase 2b CLOVER WaM trial data at ASCO 2026, showing a 79.2% MRR and a median DOR of 16 months in r/r WM patients.
• Dosed first patients in the Phase 1b trial for CLR 125 in TNBC, expanding the clinical validation of the PDC platform.
• Published positive Phase 1 data for iopofosine I 131 in r/r MM, demonstrating 84.6% disease control and a 30% ORR at higher doses.
• Strengthened balance sheet with approximately $35 million upfront and up to $105 million in potential milestone-based financing, providing runway into Q2 2027.
• Reduced General and Administrative expenses by approximately $1 million compared to the prior year's quarter.
• Received multiple FDA designations for iopofosine I 131, including Breakthrough Therapy and Orphan Drug designations for various indications.

Negatives

• Reported a net loss of $6.9 million for the three months ended June 30, 2026, compared to $5.4 million in the prior year.
• Net loss per share increased significantly to $0.57 from $3.39 in the prior year's quarter due to a higher number of outstanding shares.
• Research and Development expenses nearly doubled to $4.6 million from $2.4 million year-over-year, reflecting increased clinical trial activity.

Risks

• The ability to identify suitable collaborators, partners, licensees or purchasers for product candidates.
• The ability to enter into binding agreements for collaborations or partnerships.
• The ability to raise additional capital to support operations.
• Uncertainties related to the successful completion of clinical trials and regulatory approvals.
• The potential for adverse safety profiles or lack of efficacy in ongoing and future clinical trials.
• Competition from other companies developing treatments for similar cancer indications.

Future Outlook

The company anticipates submitting its New Drug Application for iopofosine I 131 in mid-2027 under the FDA's Accelerated Approval Program. The cash balance is expected to fund operations into the second quarter of 2027. Multiple data and development milestones are anticipated in the second half of 2026.

Management Comments

• "Our second quarter marked another period of significant execution as we continued to advance multiple programs across our oncology pipeline while laying the foundation for several important near-term catalysts."
• "Most notably, we progressed our regulatory strategy for iopofosine I 131 in Waldenstrm macroglobulinemia, including initiation of site activation activities for our confirmatory Phase 3 trial, which is an important first step toward our accelerated approval application in the U.S., which we plan to submit in mid-2027."
• "The compelling data we continue to generate from the Phase 2b CLOVER WaM study reinforce our belief that iopofosine has the potential to address a critical unmet need for WM patients, including those previously treated with BTK inhibitors and prior to off-label salvage therapies."
• "Supported by a strengthened balance sheet and a clear operational roadmap, we are entering the second half of 2026 with strong momentum, multiple anticipated data and development milestones, and a steadfast commitment to creating long-term value for patients and stockholders."

Industry Context

StockSavvy.ai notes that Cellectar's progress aligns with the broader biopharmaceutical industry trend of focusing on targeted therapies and leveraging accelerated approval pathways for oncology drugs, particularly for rare or refractory conditions.

Comparison to Industry Standards

• The MRR of 79.2% for iopofosine I 131 in r/r WM patients post-BTKi therapy is a strong indicator, though direct comparisons are difficult without specific industry benchmarks for this exact patient subgroup and treatment stage.
• The planned mid-2027 NDA submission under the FDA's Accelerated Approval Program is a common strategy in oncology, aiming to expedite patient access to potentially life-saving treatments.
• The increase in R&D spending is typical for late-stage clinical-stage biopharmaceutical companies advancing multiple drug candidates through pivotal trials.

Related Party Transactions

• In May 2026, the company entered into a securities purchase agreement with certain institutional investors and members of executive management for a registered direct offering and concurrent private placement.

Stakeholder Impact

• Shareholders: The capital raise strengthens the company's financial position, potentially supporting long-term value creation, but also dilutes existing shareholders due to the issuance of new securities.
• Patients: Continued progress in clinical trials for iopofosine I 131 and CLR 125 offers potential new treatment options for cancer patients with unmet needs.
• Creditors: The increased cash balance improves the company's ability to meet its financial obligations.

Next Steps

• Initiate Phase 3 confirmatory trial for iopofosine I 131 in WM, with first patient dosing expected in early 2027.
• Submit New Drug Application for iopofosine I 131 in mid-2027 under the FDA's Accelerated Approval Program.
• Continue enrollment and dosing in the Phase 1b trial of CLR 125 in TNBC to determine recommended Phase 2 dose.
• Continue development of other pipeline assets, including CLR 125 (iodine-125) and CLR 225 (actinium-225) based programs.

Key Dates

Recommendation

The company is making significant progress in its clinical pipeline and has secured necessary funding, which are positive indicators. However, the widening net loss, increased R&D expenses, and the inherent risks associated with late-stage drug development warrant a cautious 'hold' rating until further clinical data and regulatory milestones are achieved.

Keywords

iopofosine I 131, Waldenstrm Macroglobulinemia, CLR 125, Triple Negative Breast Cancer, Phospholipid Drug Conjugate, clinical trials, oncology, biopharmaceutical